Clinical Trial Update: A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing safety, tolerability, and activity of TD-1211 in patients with opioid-induced constipation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• TD-1211

Snippet

Sponsor: Theravance Biopharma | Conditions: Opioid-induced Constipation (OIC) | Phase 2 | Status: COMPLETED